PedAM
Pediatric Disease Annotations & Medicines
| Disease | chagas disease |
| Phenotype | C0018801|heart failure |
| Sentences | 17 |
| PubMedID- 23152267 | Authors' conclusions: this cochrane review has found a lack of evidence on the effects of carvedilol for treating heart failure in patients with chagas disease. |
| PubMedID- 20502520 | Nearly 60% of symptomatic congestive heart failure was due to chagas disease; mortality was also higher for infected than uninfected patients. |
| PubMedID- 23272265 | In human clinical studies of patients with end-stage heart failure due to chagas disease the administration of autologous bone marrow mononuclear cells did not improve cardiac function [19]. |
| PubMedID- 24705159 | Initially caused by the parasite trypanosoma cruzi, the chagas disease may lead to a heart failure and a sudden death upon disease progression. |
| PubMedID- 25886035 | If untreated, chagas disease can lead to heart failure and death. |
| PubMedID- 21484040 | chagas disease was the cause of heart failure in 92 (20.4%) patients who had higher b type natriuretic peptide levels (1,978.38 vs. 1,697.64 pg/ml; p = 0.015). |
| PubMedID- 26407508 | After a decade or more, 20% to 30% of people will experience chronic cardiovascular chagas disease with sequelae including heart failure, arrhythmias, and thromboembolism. |
| PubMedID- 22513344 | heart failure survival score in patients with chagas disease: correlation with functional variables. |
| PubMedID- 24918914 | Our data suggest that patients with heart failure due to chagas disease and class iiiand iv heart failure submitted to transplantation of stem cells from bone marrow to themyocardium, showed no increase in the incidence of sustained ventricular tachycardia,but showed increase in nonsustained ventricular tachycardia between holter atrandomization and holter at 6 months in the study group, as well as increased vpbdensity in the study group. |
| PubMedID- 23871619 | Cardiopulmonary exercise and 6-min walk tests as predictors of quality of life and long-term mortality among patients with heart failure due to chagas disease. |
| PubMedID- 26161401 | The group led by vilas-boas [15] enrolled 28 patients with congestive heart failure due to chagas disease in an open label, single center, uncontrolled phase 1 trial. |
| PubMedID- 21820551 | Treatment options for heart failure due to chagas disease are not different from standard therapy. |
| PubMedID- 23787193 | Methods: we retrospectively analyzed the outcome of 54 chagas disease patients without heart failure and with left ventricular (lv) ejection fraction >45% whose tgf-beta1 serum values were determined between january 1998 and december 1999. |
| PubMedID- 22558095 | Luis fabrega” in santiago city in may of 2010. the patient came from el pantano community, one of our evaluated areas, and presented a heart failure compatible with chronic chagas disease and a positive serology for t. cruzi. |
| PubMedID- 24984860 | Introduction: new therapeutic options are necessary for patients with chronic chagas disease, a leading cause of heart failure in latin american countries. |
| PubMedID- 22011801 | Conclusion: the prevalence of asymptomatic coronary artery disease in patients with severe heart failure due to chagas disease is low and among the risk factors for coronary heart disease, smoking was the most prevalent. |
| PubMedID- 24627740 | chagas disease, a major cause of heart failure (hf) in latin america, affects approximately eight million people[1] and represents a significant public health and socio-economic problem in these countries. |
Page: 1